Business Wire

JAPAN-CORN-STARCH

17.2.2017 01:54:37 CET | Business Wire | Press release

Share
Japan Corn Starch Co., Ltd. Releasing the New High-Fructose Corn Syrup, "HFCS 70"!!

Japan Corn Starch Co., Ltd. (Minato-ku, Tokyo; Soichiro Kurachi, president. Hereby, “Japan Corn Starch” or “the company”), the largest corn wet miller in Japan has been pursuing excellent flavor in the increasingly diverse food industry, and conducting research to find the perfect balance of fructose and glucose in high-fructose corn syrup (HFCS), used in a variety of soft drinks. The company successfully developed and obtained patent for a new product, “HFCS 70” that maintains the body equal to fructose glucose liquid sugar used in many soft drinks while having the sharp sweetness of fructose, and is about to release the product.

Since its development 50 years ago, there were only three varieties of HFCS until this year, glucose-fructose liquid sugar, fructose-glucose liquid sugar, and high-fructose liquid sugar, commoditization of which made their differentiation difficult. However, by introducing HFCS 70 into the market, the company expects to overturn the stereotypes in the HFCS industry and create a new wind in the industry.

Japan Corn Starch’s new product, HFCS 70 maintains the body while realizing a high level of sharp sweetness. This allows the product to create a flavor different from fructose glucose liquid sugar, high fructose liquid sugar, or crystalline fructose that are mainstream in the soft drink industry, and help the development of delicious drinks with a new type of sweetness. In addition, because HFCS maintains the body while realizing a high level of sharp sweetness, it can be used in products such as highly refreshing and filling jellies.

Japan Corn Starch has obtained licenses such as the first FSSC22000 and HACCP in the industry and ISO22301, which is the international standard for business continuity management system (BCMS). Furthermore, the company has been making efforts such as radiation dose measurement of each product using high-performance equipment, and quantification of odor using odor identification devices. Thus the company is fully equipped for stable distribution of products.

As a comprehensive producer of starch-related products, Japan Corn Starch will continue its commitment to offer reliable, safe, and high quality products that cater our clients’ every need through its thoroughgoing distribution system.

About the Company

Company name: Japan Corn Starch Co., Ltd.
President: Soichiro Kurachi
Head office: Akasaka Inter City 3F, 1-11-44 Akasaka, Minato Ward, Tokyo, 107-0052
Tel: +81-3-5570-7000 (operator)
Fax: +81-3-5570-7001
Mail: corn@japan-cornstarch.com
URL: http://www.nihon-cornstarch.com/english
Founded: 1867

Contact:

Japan Corn Starch Co., Ltd.
Kazuki Hashimoto, +81-566-42-3129
Public Relations
corn@japan-cornstarch.com
http://www.nihon-cornstarch.com/english
fax: +81-3-5570-7001

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye